(HealthDay News) — There is currently insufficient data to support the use of β-blockers for all patients with clinically stable coronary heart disease (SCHD), according to a paper published in the November 15 issue of The American Journal of Cardiology.

David E. Winchester, MD, and Carl J. Pepine, MD, from the University of Florida College of Medicine in Gainesville, discuss the use of β-blockers for patients with SCHD.

The researchers note that β-blockers are assumed to be beneficial in SCHD based on older data, established before widespread use of reperfusion interventions, modern medical therapy, or preventive treatments. Their use has been extrapolated beyond patients with heart failure and previous myocardial infarction, which have the best evidence for efficacy. No randomized clinical trials from the modern era are available demonstrating that β-blockers reduce clinical events in SCHD. In addition, β-blocker use is not without risk, with use correlating with weight gain, glycemic control problems, fatigue, and bronchospasm.

“In conclusion, data are currently lacking to support the widespread use of β-blockers for all SCHD patients, but contemporary data suggest that they be reserved for a well-defined high-risk group of patients with evidence of ongoing ischemia, left ventricular dysfunction, heart failure, and perhaps some arrhythmias,” the authors write.

The development of the manuscript was supported by Gilead Sciences.

Full Text (subscription or payment may be required)